US 9279019
Human monoclonal antibodies specific for CD22
granted A61KA61K2039/505A61K38/164
Quick answer
US patent 9279019 (Human monoclonal antibodies specific for CD22) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America as Represented by the Secretary of the Department of Health and Human Services
- Grant date
- Tue Mar 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K2039/505, A61K38/164, A61K38/45, A61K39/00